Key result
The Medtronic Sprint Fidelis ICD lead was voluntarily recalled after 38 months on the U.S. market and 268,000 implantations worldwide because of its propensity to fracture.
Answers are grounded in this paper and cite their sources.
The recall of the Sprint Fidelis ICD lead highlights the risks of FDA device approval based solely on bench testing without human clinical data.
When the Food and Drug Administration (FDA) approved the Medtronic Sprint Fidelis implantable cardioverter–defibrillator (ICD) lead in 2004 on the basis of bench testing but no human clinical data, there was no public outcry. Physicians rapidly incorporated the new electrode into their practice, welcoming its small diameter and ease of implantation. During the ensuing 3 years, 90% of Medtronic ICDs were implanted with this lead (see diagram). But in October 2007, after 38 months on the U.S. market and 268,000 implantations worldwide, the Fidelis was voluntarily recalled by Medtronic because of its propensity to fracture. The large number of affected . . .
No takes yet. Share an insight, caveat, or question.
William H. Maisel (2008) conducted an editorial in Implantable cardioverter-defibrillator (ICD) indication (n=268,000). Medtronic Sprint Fidelis ICD lead was evaluated on Lead fracture. The Medtronic Sprint Fidelis ICD lead was voluntarily recalled after 38 months on the U.S. market and 268,000 implantations worldwide because of its propensity to fracture.
Synapse has enriched 10 related papers. Consider them for comparative context: